{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T05:16:08Z","timestamp":1784438168240,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":141,"publisher":"Springer New York","isbn-type":[{"value":"9781493989751","type":"print"},{"value":"9781493989768","type":"electronic"}],"license":[{"start":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T00:00:00Z","timestamp":1546041600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/978-1-4939-8976-8_1","type":"book-chapter","created":{"date-parts":[[2018,12,28]],"date-time":"2018-12-28T08:24:17Z","timestamp":1545985457000},"page":"3-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus"],"prefix":"10.1007","author":[{"given":"Darrick K.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,29]]},"reference":[{"key":"1_CR1","first-page":"1904","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"SC Ray","year":"2015","unstructured":"Ray SC, Thomas DL (2015) Hepatitis C. In: Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases, 8th edn. Elsevier Saunders, Philadelphia, pp 1904\u20131927","edition":"8"},{"key":"1_CR2","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","volume":"108","author":"MH Powdrill","year":"2011","unstructured":"Powdrill MH, Tchesnokov EP, Kozak RA, Russell RS, Martin R, Svarovskaia ES et al (2011) Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A 108:20509\u201320513","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333\u20131342","journal-title":"Hepatology"},{"key":"1_CR4","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(75)90234-2","volume":"306","author":"HJ Alter","year":"1975","unstructured":"Alter HJ, Holland PV, Morrow AG, Purcell RH, Feinstone SM, Moritsugu Y (1975) Clinical and serological analysis of transfusion-associated hepatitis. Lancet 306:838\u2013841","journal-title":"Lancet"},{"key":"1_CR5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM197504102921502","volume":"292","author":"SM Feinstone","year":"1975","unstructured":"Feinstone SM, Kapikian AZ, Purcell RH, Alter HJ, Holland PV (1975) Transfusion-associated hepatitis not due to viral hepatitis type A or B. N Engl J Med 292:767\u2013770","journal-title":"N Engl J Med"},{"key":"1_CR6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","volume":"315","author":"JH Hoofnagle","year":"1986","unstructured":"Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M et al (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med 315:1575\u20131578","journal-title":"N Engl J Med"},{"key":"1_CR7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359\u2013362","journal-title":"Science"},{"key":"1_CR8","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1056\/NEJM198911303212203","volume":"321","author":"GL Davis","year":"1989","unstructured":"Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP et al (1989) Treatment of chronic hepatitis C with recombinant interferon alfa. N Engl J Med 321:1501\u20131506","journal-title":"N Engl J Med"},{"key":"1_CR9","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM198911303212204","volume":"321","author":"AM Bisceglie Di","year":"1989","unstructured":"Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J et al (1989) Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med 321:1506\u20131510","journal-title":"N Engl J Med"},{"key":"1_CR10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","volume":"339","author":"JG McHutchison","year":"1998","unstructured":"McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al (1998) Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339:1485\u20131492","journal-title":"N Engl J Med"},{"key":"1_CR11","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gon\u00e7ales FL et al (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975\u2013982","journal-title":"N Engl J Med"},{"key":"1_CR12","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958\u2013965","journal-title":"Lancet"},{"key":"1_CR13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJM199506013322201","volume":"332","author":"T Poynard","year":"1995","unstructured":"Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C et al (1995) A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 332:1457\u20131463","journal-title":"N Engl J Med"},{"key":"1_CR14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nm1268","volume":"11","author":"T Wakita","year":"2005","unstructured":"Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z et al (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791\u2013796","journal-title":"Nat Med"},{"key":"1_CR15","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH et al (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364:2405\u20132416","journal-title":"N Engl J Med"},{"key":"1_CR16","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","volume":"364","author":"F Poordad","year":"2011","unstructured":"Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364:1195\u20131206","journal-title":"N Engl J Med"},{"key":"1_CR17","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y et al (2014) Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 384:414\u2013426","journal-title":"Lancet"},{"key":"1_CR18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cld.2011.05.003","volume":"15","author":"FE Membreno","year":"2011","unstructured":"Membreno FE, Lawitz EJ (2011) The HCV NS5B nucleoside and non-nucleoside inhibitors. Clin Liver Dis 15:611\u2013626","journal-title":"Clin Liver Dis"},{"key":"1_CR19","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC et al (2013) Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 368:1878\u20131887","journal-title":"N Engl J Med"},{"key":"1_CR20","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1214854","volume":"368","author":"IM Jacobson","year":"2013","unstructured":"Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS et al (2013) Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 368:1867\u20131877","journal-title":"N Engl J Med"},{"key":"1_CR21","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483\u20131493","journal-title":"N Engl J Med"},{"key":"1_CR22","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889\u20131898","journal-title":"N Engl J Med"},{"key":"1_CR23","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E et al (2014) Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 370:1879\u20131888","journal-title":"N Engl J Med"},{"key":"1_CR24","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A et al (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756\u20131765","journal-title":"Lancet"},{"key":"1_CR25","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","volume":"370","author":"JJ Feld","year":"2014","unstructured":"Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D et al (2014) Treatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1594\u20131603","journal-title":"N Engl J Med"},{"key":"1_CR26","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K et al (2014) ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973\u20131982","journal-title":"N Engl J Med"},{"key":"1_CR27","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1053\/j.gastro.2015.10.013","volume":"150","author":"MS Sulkowski","year":"2016","unstructured":"Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK et al (2016) Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology 150:419\u2013429","journal-title":"Gastroenterology"},{"key":"1_CR28","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2016.08.004","volume":"151","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM et al (2016) Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology 151:1131\u20131140.e1135","journal-title":"Gastroenterology"},{"key":"1_CR29","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1136\/gutjnl-2016-311609","volume":"66","author":"TM Welzel","year":"2016","unstructured":"Welzel TM, Nelson DR, Morelli G, Di Bisceglie A, Reddy RK, Kuo A et al (2016) Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 66:1844\u20131852","journal-title":"Gut"},{"key":"1_CR30","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cid\/ciw387","volume":"63","author":"JJ Feld","year":"2016","unstructured":"Feld JJ, Maan R, Zeuzem S, Kuo A, Nelson DR, Di Bisceglie AM et al (2016) Effectiveness and safety of Sofosbuvir-based regimens for chronic HCV genotype 3 infection: results of the HCV-TARGET study. Clin Infect Dis 63:776\u2013783","journal-title":"Clin Infect Dis"},{"key":"1_CR31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/apt.13823","volume":"45","author":"KR Reddy","year":"2016","unstructured":"Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G et al (2016) All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther 45:115\u2013126","journal-title":"Aliment Pharmacol Ther"},{"key":"1_CR32","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2004.06.005","volume":"127","author":"T Laskus","year":"2004","unstructured":"Laskus T, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M et al (2004) Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology 127:764\u2013776","journal-title":"Gastroenterology"},{"key":"1_CR33","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1128\/JVI.66.5.3225-3229.1992","volume":"66","author":"M Martell","year":"1992","unstructured":"Martell M, Esteban JI, Quer J, Genesca J, Weiner A, Esteban R et al (1992) Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 66:3225\u20133229","journal-title":"J Virol"},{"key":"1_CR34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2015.03.022","volume":"479-480","author":"R Andino","year":"2015","unstructured":"Andino R, Domingo E (2015) Viral quasispecies. Virology 479-480:46\u201351","journal-title":"Virology"},{"key":"1_CR35","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/v7112902","volume":"7","author":"C Perales","year":"2015","unstructured":"Perales C, Quer J, Gregori J, Esteban J, Domingo E (2015) Resistance of hepatitis C virus to inhibitors: complexity and clinical implications. Viruses 7:5746\u20135766","journal-title":"Viruses"},{"key":"1_CR36","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1099\/0022-1317-81-7-1631","volume":"81","author":"R Bartenschlager","year":"2000","unstructured":"Bartenschlager R, Lohmann V (2000) Replication of hepatitis C virus. J Gen Virol 81:1631\u20131648","journal-title":"J Gen Virol"},{"key":"1_CR37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann AU (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-therapy. Science 282:103\u2013107","journal-title":"Science"},{"key":"1_CR38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"J-M Pawlotsky","year":"2016","unstructured":"Pawlotsky J-M (2016) Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 151:70\u201386","journal-title":"Gastroenterology"},{"key":"1_CR39","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/j.gastro.2012.02.027","volume":"142","author":"S Chevaliez","year":"2012","unstructured":"Chevaliez S, Rodriguez C, Pawlotsky JM (2012) New virologic tools for management of chronic hepatitis B and C. Gastroenterology 142:1303\u20131313.e1301","journal-title":"Gastroenterology"},{"key":"1_CR40","doi-asserted-by":"crossref","first-page":"831","DOI":"10.4254\/wjh.v7.i6.831","volume":"7","author":"N Echeverria","year":"2015","unstructured":"Echeverria N, Moratorio G, Cristina J, Moreno P (2015) Hepatitis C virus genetic variability and evolution. World J Hepatol 7:831\u2013845","journal-title":"World J Hepatol"},{"key":"1_CR41","first-page":"120","volume":"15","author":"T Leitner","year":"1993","unstructured":"Leitner T, Halapi E, Scarlatti G, Rossi P, Albert J, Fenyo EM et al (1993) Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques 15:120\u2013127","journal-title":"BioTechniques"},{"key":"1_CR42","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.3390\/v7122941","volume":"7","author":"S Fourati","year":"2015","unstructured":"Fourati S, Pawlotsky J-M (2015) Virologic tools for HCV drug resistance testing. Viruses 7:6346\u20136359","journal-title":"Viruses"},{"key":"1_CR43","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/JCM.05715-11","volume":"50","author":"M Ninomiya","year":"2011","unstructured":"Ninomiya M, Ueno Y, Funayama R, Nagashima T, Nishida Y, Kondo Y et al (2011) Use of Illumina deep sequencing technology to differentiate hepatitis C virus variants. J Clin Microbiol 50:857\u2013866","journal-title":"J Clin Microbiol"},{"key":"1_CR44","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1128\/JCM.00330-16","volume":"54","author":"E Thomson","year":"2016","unstructured":"Thomson E, Ip CLC, Badhan A, Christiansen MT, Adamson W, Ansari MA et al (2016) Comparison of next-generation sequencing technologies for comprehensive assessment of full-length hepatitis C viral genomes. J Clin Microbiol 54:2470\u20132484","journal-title":"J Clin Microbiol"},{"key":"1_CR45","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","volume":"55","author":"P Halfon","year":"2011","unstructured":"Halfon P, Locarnini S (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55:192\u2013206","journal-title":"J Hepatol"},{"key":"1_CR46","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(10)60934-8","volume":"376","author":"PY Kwo","year":"2010","unstructured":"Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D et al (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376:705\u2013716","journal-title":"Lancet"},{"key":"1_CR47","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R et al (2009) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360:1827\u20131838","journal-title":"N Engl J Med"},{"key":"1_CR48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.coph.2016.07.015","volume":"30","author":"JA McCauley","year":"2016","unstructured":"McCauley JA, Rudd MT (2016) Hepatitis C virus NS3\/4a protease inhibitors. Curr Opin Pharmacol 30:84\u201392","journal-title":"Curr Opin Pharmacol"},{"key":"1_CR49","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2014.11.032","volume":"62","author":"O Lenz","year":"2015","unstructured":"Lenz O, Verbinnen T, Fevery B, Tambuyzer L, Vijgen L, Peeters M et al (2015) Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon\/ribavirin in phase IIb\/III studies. J Hepatol 62:1008\u20131014","journal-title":"J Hepatol"},{"key":"1_CR50","doi-asserted-by":"crossref","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","volume":"7","author":"TL Kieffer","year":"2012","unstructured":"Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A et al (2012) Hepatitis C viral evolution in genotype 1 treatment-na\u00efve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 7:e34372","journal-title":"PLoS One"},{"key":"1_CR51","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J et al (2010) In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother 54:1878\u20131887","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR52","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1093\/cid\/ciu696","volume":"59","author":"AYM Howe","year":"2014","unstructured":"Howe AYM, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJO et al (2014) Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon\/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis 59:1657\u20131665","journal-title":"Clin Infect Dis"},{"key":"1_CR53","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1128\/AAC.04227-14","volume":"59","author":"T Pilot-Matias","year":"2014","unstructured":"Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L et al (2014) In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3\/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59:988\u2013997","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR54","doi-asserted-by":"crossref","first-page":"4161","DOI":"10.1128\/AAC.00324-12","volume":"56","author":"V Summa","year":"2012","unstructured":"Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C, Claudio G et al (2012) MK-5172, a selective inhibitor of hepatitis C virus NS3\/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother 56:4161\u20134167","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR55","first-page":"113","volume":"369","author":"D Moradpour","year":"2013","unstructured":"Moradpour D, Penin F (2013) Hepatitis C virus proteins: from structure to function. Curr Top Microbiol Immunol 369:113\u2013142","journal-title":"Curr Top Microbiol Immunol"},{"key":"1_CR56","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1306227","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S et al (2014) Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 370:222\u2013232","journal-title":"N Engl J Med"},{"key":"1_CR57","doi-asserted-by":"publisher","unstructured":"Howe JA, Long J, Black S, Chase R, McMonagle P, Curry S et al (2014) Clinical implications of detectable baseline hepatitis C virus-genotype 1 NS3\/4A-protease variants on the efficacy of boceprevir combined with peginterferon\/ribavirin. Open Forum Infect Dis 1. https:\/\/doi.org\/10.1093\/ofid\/ofu078","DOI":"10.1093\/ofid\/ofu078"},{"key":"1_CR58","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1128\/AAC.01953-15","volume":"59","author":"SB Jensen","year":"2015","unstructured":"Jensen SB, Serre SBN, Humes DG, Ramirez S, Li Y-P, Bukh J et al (2015) Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother 59:7426\u20137436","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR59","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.1128\/AAC.01578-13","volume":"57","author":"M Jiang","year":"2013","unstructured":"Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D et al (2013) In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother 57:6236\u20136245","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR60","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.antiviral.2013.05.015","volume":"99","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M et al (2013) Characterization of vaniprevir, a hepatitis C virus NS3\/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antivir Res 99:214\u2013220","journal-title":"Antivir Res"},{"key":"1_CR61","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1128\/AAC.00308-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F et al (2012) Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 56:3670\u20133681","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR62","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/AAC.02929-15","volume":"60","author":"SBN Serre","year":"2016","unstructured":"Serre SBN, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li Y-P et al (2016) Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle. Antimicrob Agents Chemother 60:3563\u20133578","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR63","doi-asserted-by":"crossref","first-page":"7548","DOI":"10.1128\/AAC.01444-15","volume":"59","author":"T Verbinnen","year":"2015","unstructured":"Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O (2015) In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob Agents Chemother 59:7548\u20137557","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","volume":"64","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486\u2013504","journal-title":"J Hepatol"},{"key":"1_CR65","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cid\/cit226","volume":"57","author":"JC Sullivan","year":"2013","unstructured":"Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J et al (2013) Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 57:221\u2013229","journal-title":"Clin Infect Dis"},{"key":"1_CR66","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cid\/civ722","volume":"62","author":"M Buti","year":"2015","unstructured":"Buti M, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H et al (2015) Grazoprevir, Elbasvir, and Ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE: table 1. Clin Infect Dis 62:32\u201336","journal-title":"Clin Infect Dis"},{"key":"1_CR67","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2013.03.030","volume":"59","author":"J-M Pawlotsky","year":"2013","unstructured":"Pawlotsky J-M (2013) NS5A inhibitors in the treatment of hepatitis C. J Hepatol 59:375\u2013382","journal-title":"J Hepatol"},{"key":"1_CR68","doi-asserted-by":"crossref","first-page":"40835","DOI":"10.1074\/jbc.M404761200","volume":"279","author":"F Penin","year":"2004","unstructured":"Penin F, Brass V, Appel N, Ramboarina S, Montserret R, Ficheux D et al (2004) Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J Biol Chem 279:40835\u201340843","journal-title":"J Biol Chem"},{"key":"1_CR69","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pro.2456","volume":"23","author":"SM Lambert","year":"2014","unstructured":"Lambert SM, Langley DR, Garnett JA, Angell R, Hedgethorne K, Meanwell NA et al (2014) The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci 23:723\u2013734","journal-title":"Protein Sci"},{"key":"1_CR70","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.02352-08","volume":"83","author":"RA Love","year":"2009","unstructured":"Love RA, Brodsky O, Hickey MJ, Wells PA, Cronin CN (2009) Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J Virol 83:4395\u20134403","journal-title":"J Virol"},{"key":"1_CR71","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nature03580","volume":"435","author":"TL Tellinghuisen","year":"2005","unstructured":"Tellinghuisen TL, Marcotrigiano J, Rice CM (2005) Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 435:374\u2013379","journal-title":"Nature"},{"key":"1_CR72","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.ijid.2008.05.437","volume":"12","author":"B Chassey de","year":"2008","unstructured":"de Chassey B, Navratil V, Tafforeau L, Andre P, Rabourdin-Combe C, Lotteau V (2008) Hepatitis C virus infection protein network. Int J Infect Dis 12:e175","journal-title":"Int J Infect Dis"},{"key":"1_CR73","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1053\/j.gastro.2014.07.019","volume":"147","author":"C Berger","year":"2014","unstructured":"Berger C, Romero-Brey I, Radujkovic D, Terreux R, Zayas M, Paul D et al (2014) Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus\u2013induced membranous replication factories, independent of RNA replication. Gastroenterology 147:1094\u20131105.e1025","journal-title":"Gastroenterology"},{"key":"1_CR74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA et al (2010) Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96\u2013100","journal-title":"Nature"},{"key":"1_CR75","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, Valera L, Gao M (2010) Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother 54:3641\u20133650","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR76","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.virol.2011.03.026","volume":"414","author":"C Lee","year":"2011","unstructured":"Lee C, Ma H, Hang JQ, Leveque V, Sklan EH, Elazar M et al (2011) The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 414:10\u201318","journal-title":"Virology"},{"key":"1_CR77","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrmicro3046","volume":"11","author":"R Bartenschlager","year":"2013","unstructured":"Bartenschlager R, Lohmann V, Penin F (2013) The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol 11:482\u2013496","journal-title":"Nat Rev Microbiol"},{"key":"1_CR78","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1128\/JVI.02294-12","volume":"87","author":"DJ Bartels","year":"2012","unstructured":"Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S et al (2012) Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 87:1544\u20131553","journal-title":"J Virol"},{"key":"1_CR79","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3851\/IMP2091","volume":"17","author":"Z Plaza","year":"2012","unstructured":"Plaza Z, Soriano V, Vispo E, del Mar Gonzalez M, Barreiro P, Secl\u00e9n E et al (2012) Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. Antivir Ther 17:921\u2013926","journal-title":"Antivir Ther"},{"key":"1_CR80","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/AAC.05977-11","volume":"56","author":"C Wang","year":"2012","unstructured":"Wang C, Huang H, Valera L, Sun JH, O'Boyle DR, Nower PT et al (2012) Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052. Antimicrob Agents Chemother 56:1350\u20131358","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR81","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1128\/AAC.06169-11","volume":"56","author":"C Wang","year":"2011","unstructured":"Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X et al (2011) In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother 56:1588\u20131590","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR82","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1128\/AAC.02788-14","volume":"58","author":"C Wang","year":"2014","unstructured":"Wang C, Jia L, O'Boyle DR, Sun JH, Rigat K, Valera L et al (2014) Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother 58:5155\u20135163","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR83","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1128\/AAC.01874-12","volume":"57","author":"C Wang","year":"2012","unstructured":"Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA (2012) In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother 57:611\u2013613","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.gastro.2016.06.002","volume":"151","author":"C Sarrazin","year":"2016","unstructured":"Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang S-M et al (2016) Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology 151:501\u2013512.e501","journal-title":"Gastroenterology"},{"key":"1_CR85","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","volume":"60","author":"G Cheng","year":"2016","unstructured":"Cheng G, Tian Y, Doehle B, Peng B, Corsa A, Lee Y-J et al (2016) In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother 60:1847\u20131853","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR86","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","volume":"59","author":"P Krishnan","year":"2014","unstructured":"Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D et al (2014) In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59:979\u2013987","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR87","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep.22549","volume":"48","author":"T Kuntzen","year":"2008","unstructured":"Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK et al (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients. Hepatology 48:1769\u20131778","journal-title":"Hepatology"},{"key":"1_CR88","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1128\/AAC.00051-16","volume":"60","author":"FC Lahser","year":"2016","unstructured":"Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P et al (2016) The combination of grazoprevir, a hepatitis C virus (HCV) NS3\/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother 60:2954\u20132964","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR89","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1128\/AAC.00763-16","volume":"60","author":"EJ Lawitz","year":"2016","unstructured":"Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM et al (2016) Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother 60:5368\u20135378","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR90","doi-asserted-by":"crossref","first-page":"6922","DOI":"10.1128\/AAC.01390-15","volume":"59","author":"R Liu","year":"2015","unstructured":"Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA et al (2015) Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother 59:6922\u20136929","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR91","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1743-422X-10-355","volume":"10","author":"S Paolucci","year":"2013","unstructured":"Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G et al (2013) Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-na\u00efve patients. Virol J 10:355","journal-title":"Virol J"},{"key":"1_CR92","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/AAC.02193-12","volume":"57","author":"KA Wong","year":"2013","unstructured":"Wong KA, Worth A, Martin R, Svarovskaia E, Brainard DM, Lawitz E et al (2013) Characterization of hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57:6333\u20136340","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR93","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/jmv.24255","volume":"87","author":"S Yoshimi","year":"2015","unstructured":"Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M, Kawakami Y et al (2015) Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 87:1913\u20131920","journal-title":"J Med Virol"},{"key":"1_CR94","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1128\/AAC.02606-15","volume":"60","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X et al (2015) Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir. Antimicrob Agents Chemother 60:1106\u20131113","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR95","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.3390\/v7102868","volume":"7","author":"A Eltahla","year":"2015","unstructured":"Eltahla A, Luciani F, White P, Lloyd A, Bull R (2015) Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 7:5206\u20135224","journal-title":"Viruses"},{"key":"1_CR96","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1517\/14656566.2013.795543","volume":"14","author":"V Soriano","year":"2013","unstructured":"Soriano V, Vispo E, de Mendoza C, Labarga P, Fernandez-Montero JV, Poveda E et al (2013) Hepatitis C therapy with HCV NS5B polymerase inhibitors. Expert Opin Pharmacother 14:1161\u20131170","journal-title":"Expert Opin Pharmacother"},{"key":"1_CR97","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.2174\/0929867322666150625094705","volume":"22","author":"E Clercq De","year":"2015","unstructured":"De Clercq E (2015) Curious (old and new) antiviral nucleoside analogues with intriguing therapeutic potential. Curr Med Chem 22:3866\u20133880","journal-title":"Curr Med Chem"},{"key":"1_CR98","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0969-2126(00)80031-3","volume":"7","author":"H Ago","year":"1999","unstructured":"Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K et al (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417\u20131426","journal-title":"Structure"},{"key":"1_CR99","doi-asserted-by":"crossref","first-page":"13034","DOI":"10.1073\/pnas.96.23.13034","volume":"96","author":"S Bressanelli","year":"1999","unstructured":"Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M et al (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc Natl Acad Sci U S A 96:13034\u201313039","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1_CR100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/13305","volume":"6","author":"CA Lesburg","year":"1999","unstructured":"Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol 6:937\u2013943","journal-title":"Nat Struct Biol"},{"key":"1_CR101","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1128\/AAC.00054-12","volume":"56","author":"AM Lam","year":"2012","unstructured":"Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V et al (2012) Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359\u20133368","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/hep.27375","volume":"61","author":"EF Donaldson","year":"2014","unstructured":"Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK (2014) Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 61:56\u201365","journal-title":"Hepatology"},{"key":"1_CR103","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(13)70033-1","volume":"13","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM et al (2013) Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 13:401\u2013408","journal-title":"Lancet Infect Dis"},{"key":"1_CR104","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","volume":"59","author":"ES Svarovskaia","year":"2014","unstructured":"Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R et al (2014) Infrequent development of resistance in genotype 1\u20136 hepatitis C virus\u2013infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 59:1666\u20131674","journal-title":"Clin Infect Dis"},{"key":"1_CR105","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/infdis\/jiv564","volume":"213","author":"ES Svarovskaia","year":"2015","unstructured":"Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C et al (2015) L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis 213:1240\u20131247","journal-title":"J Infect Dis"},{"key":"1_CR106","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourli\u00e8re M et al (2014) Retreatment of HCV with ABT-450\/r\u2013ombitasvir and dasabuvir with ribavirin. N Engl J Med 370:1604\u20131614","journal-title":"N Engl J Med"},{"key":"1_CR107","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1128\/AAC.02386-13","volume":"58","author":"VC Maio Di","year":"2014","unstructured":"Di Maio VC, Cento V, Mirabelli C, Artese A, Costa G, Alcaro S et al (2014) Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 58:2781\u20132797","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR108","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1128\/AAC.00998-15","volume":"59","author":"P Krishnan","year":"2015","unstructured":"Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M et al (2015) Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother 59:5445\u20135454","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR109","doi-asserted-by":"crossref","first-page":"e0160668","DOI":"10.1371\/journal.pone.0160668","volume":"11","author":"KL Berger","year":"2016","unstructured":"Berger KL, Sarrazin C, Nelson DR, Scherer J, Sha N, Marquis M et al (2016) Resistance analyses of HCV NS3\/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir. PLoS One 11:e0160668","journal-title":"PLoS One"},{"key":"1_CR110","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1128\/AAC.04619-14","volume":"59","author":"W Kati","year":"2014","unstructured":"Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P et al (2014) In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59:1505\u20131511","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2007.04.005","volume":"76","author":"L Lu","year":"2007","unstructured":"Lu L, Dekhtyar T, Masse S, Pithawalla R, Krishnan P, He W et al (2007) Identification and characterization of mutations conferring resistance to an HCV RNA-dependent RNA polymerase inhibitor in vitro. Antivir Res 76:93\u201397","journal-title":"Antivir Res"},{"key":"1_CR112","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virol.2014.12.037","volume":"477","author":"H Ji","year":"2015","unstructured":"Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB et al (2015) Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 477:1\u20139","journal-title":"Virology"},{"key":"1_CR113","doi-asserted-by":"crossref","first-page":"39260","DOI":"10.1074\/jbc.M506407200","volume":"280","author":"G Kukolj","year":"2005","unstructured":"Kukolj G, McGibbon GA, McKercher G, Marquis M, Lef\u00e8bvre S, Thauvette L et al (2005) Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. J Biol Chem 280:39260\u201339267","journal-title":"J Biol Chem"},{"key":"1_CR114","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1473-3099(15)00529-0","volume":"16","author":"A Abergel","year":"2016","unstructured":"Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H et al (2016) Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 16:459\u2013464","journal-title":"Lancet Infect Dis"},{"key":"1_CR115","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","volume":"64","author":"A Abergel","year":"2016","unstructured":"Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS et al (2016) Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64:1049\u20131056","journal-title":"Hepatology"},{"key":"1_CR116","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1473-3099(15)70050-2","volume":"15","author":"M Bourli\u00e8re","year":"2015","unstructured":"Bourli\u00e8re M, Bronowicki J-P, de Ledinghen V, H\u00e9zode C, Zoulim F, Mathurin P et al (2015) Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 15:397\u2013404","journal-title":"Lancet Infect Dis"},{"key":"1_CR117","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr et al (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:649\u2013659","journal-title":"Gastroenterology"},{"key":"1_CR118","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1053\/j.gastro.2015.07.063","volume":"149","author":"EJ Gane","year":"2015","unstructured":"Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D et al (2015) Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149:1454\u20131461.e1451","journal-title":"Gastroenterology"},{"key":"1_CR119","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(13)62121-2","volume":"383","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H et al (2014) Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383:515\u2013523","journal-title":"Lancet"},{"key":"1_CR120","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/jvh.12549","volume":"23","author":"M Mizokami","year":"2016","unstructured":"Mizokami M, Dvory-Sobol H, Izumi N, Nishiguchi S, Doehle B, Svarovskaia ES et al (2016) Resistance analyses of Japanese hepatitis C-infected patients receiving sofosbuvir or ledipasvir\/sofosbuvir containing regimens in phase 3 studies. J Viral Hepat 23:780\u2013788","journal-title":"J Viral Hepat"},{"key":"1_CR121","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry MP, O\u2019Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618\u20132628","journal-title":"N Engl J Med"},{"key":"1_CR122","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T, Ruane PJ, Gruener N et al (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373:2599\u20132607","journal-title":"N Engl J Med"},{"key":"1_CR123","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","volume":"373","author":"GR Foster","year":"2015","unstructured":"Foster GR, Afdhal N, Roberts SK, Br\u00e4u N, Gane EJ, Pianko S et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373:2608\u20132617","journal-title":"N Engl J Med"},{"key":"1_CR124","doi-asserted-by":"crossref","first-page":"809","DOI":"10.7326\/M15-1014","volume":"163","author":"S Pianko","year":"2015","unstructured":"Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ et al (2015) Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection. Ann Intern Med 163:809","journal-title":"Ann Intern Med"},{"key":"1_CR125","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","volume":"370","author":"MS Sulkowski","year":"2014","unstructured":"Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I et al (2014) Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 370:211\u2013221","journal-title":"N Engl J Med"},{"key":"1_CR126","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR et al (2015) Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 373:714\u2013725","journal-title":"N Engl J Med"},{"key":"1_CR127","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy V, Angus P, Bronowicki J-P, Dore GJ, Hezode C, Pianko S et al (2016) Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology 63:1430\u20131441","journal-title":"Hepatology"},{"key":"1_CR128","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.01.003","volume":"116","author":"C Sarrazin","year":"2015","unstructured":"Sarrazin C, Lathouwers E, Peeters M, Daems B, Buelens A, Witek J et al (2015) Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antivir Res 116:10\u201316","journal-title":"Antivir Res"},{"key":"1_CR129","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/hep.28467","volume":"64","author":"P Kwo","year":"2016","unstructured":"Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S et al (2016) Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 64:370\u2013380","journal-title":"Hepatology"},{"key":"1_CR130","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.28422","volume":"64","author":"E Lawitz","year":"2016","unstructured":"Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R et al (2016) Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology 64:360\u2013369","journal-title":"Hepatology"},{"key":"1_CR131","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932\u2013954","journal-title":"Hepatology"},{"key":"1_CR132","first-page":"1134a","volume":"60","author":"P Krishnan","year":"2014","unstructured":"Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M et al (2014) Pooled analysis of resistance in patients treated with ombitasvir\/ABT-450\/r and dasabuvir with or without ribavirin in Phase 2 and Phase 3 clinical trials. Hepatology 60:1134a\u20131135a","journal-title":"Hepatology"},{"key":"1_CR133","doi-asserted-by":"crossref","first-page":"6807","DOI":"10.1128\/AAC.01229-15","volume":"59","author":"G Schnell","year":"2015","unstructured":"Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Lu L et al (2015) Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir\/ritonavir. Antimicrob Agents Chemother 59:6807\u20136815","journal-title":"Antimicrob Agents Chemother"},{"key":"1_CR134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ari ZB, Zhao Y et al (2015) Grazoprevir\u2013Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med 163:1\u201313","journal-title":"Ann Intern Med"},{"key":"1_CR135","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.gastro.2016.09.045","volume":"152","author":"P Kwo","year":"2017","unstructured":"Kwo P, Gane EJ, Peng C-Y, Pearlman B, Vierling JM, Serfaty L et al (2017) Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152:164\u2013175.e164","journal-title":"Gastroenterology"},{"key":"1_CR136","first-page":"1393A","volume":"62","author":"IM Jacobson","year":"2015","unstructured":"Jacobson IM, Asante-Appiah E, Wong P, Black TA, Howe AYM, Wahl J et al (2015) Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir\/grazoprevir (EBR\/GZR) against GT1a infection. Hepatology 62:1393A","journal-title":"Hepatology"},{"key":"1_CR137","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1053\/j.gastro.2016.10.017","volume":"152","author":"TE Komatsu","year":"2017","unstructured":"Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O\u2019Rear JJ et al (2017) Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology 152:586\u2013597","journal-title":"Gastroenterology"},{"key":"1_CR138","first-page":"554A","volume":"62","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Rockstroh JK, Kwo P, Roth D, Lawitz E, Sulkowski M et al (2015) Predictors of response to grazoprevir\/elbasvir among HCV genotype 1 (GT1)\u2013infected patients: integrated analysis of phase 2-3 trials. Hepatology 62:554A","journal-title":"Hepatology"},{"key":"1_CR139","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1016\/S0168-8278(17)31399-5","volume":"66","author":"P Krishnan","year":"2017","unstructured":"Krishnan P, Schnell G, Tripathi R, Ng T, Reisch T, Beyer J et al (2017) Pooled resistance analysis in HCV genotype 1\u20136-infected patients treated with glecaprevir\/pibrentasvir in phase 2 and 3 clinical trials. J Hepatol 66:S500","journal-title":"J Hepatol"},{"key":"1_CR140","first-page":"415A","volume":"64","author":"N Reau","year":"2016","unstructured":"Reau N, Nguyen MH, Kowdley KV, Gane E, Dvory-Sobol H, Svarovskaia E et al (2016) Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir, and voxilaprevir for 8 and 12 weeks from phase 2 studies. Hepatology 64:415A\u2013416A","journal-title":"Hepatology"},{"key":"1_CR141","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","volume":"376","author":"M Bourliere","year":"2017","unstructured":"Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M et al (2017) Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376:2134\u20132146","journal-title":"N Engl J Med"}],"container-title":["Methods in Molecular Biology","Hepatitis C Virus Protocols"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-8976-8_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T14:39:03Z","timestamp":1605883143000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-8976-8_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,29]]},"ISBN":["9781493989751","9781493989768"],"references-count":141,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-8976-8_1","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,29]]}}}